Innovation and Technology for Biosimilar Development
A biosimilar is an organic item very like an affirmed natural item, known as a kind of perspective item, with no clinically significant contrasts as far as wellbeing and viability. In the U.S., if a natural compound exhibits practically identical information to a U.S. Nourishment and Drug Administration (FDA)- authorized item from expository, preclinical and clinical reviews, it will be acknowledged as a biosimilar after termination of trend-setter licenses through a curtailed course. Tradable natural items are likewise Biosimilars, however should meet extra criteria to coordinate the reference item. Interchangeable can be substituted for the reference item without a medicine from a social insurance supplier.
- Biosimilar Product Reimbursement and Pricing
- Biosimilar Regulatory Updates and Legal Implications
- Biosimilar Market Access and Commercialization
Related Conference of Innovation and Technology for Biosimilar Development
2nd International Conference on Advanced Pharmacy and Clinical Research
Innovation and Technology for Biosimilar Development Conference Speakers
Recommended Sessions
- Bioequivalence Assessment
- Biologics and Biosimilars
- Biopharmaceuticals
- Biosimilars & Biologics: Clinical Studies & Trials
- Biosimilars & Biologics: Current Challenges
- Biosimilars Analytical Strategies
- Biosimilars: Pharmacovigilance and Safety
- Challenges in Biosimilars Pharmacovigilance
- Clinical Development Of Biosimilars
- Globalization of Biosimilars
- Innovation and Technology for Biosimilar Development
- Pharmaceutical Regulatory Affairs And IPR
- Regulatory Approach for Biosimilars
- Therapeutic Biological Products